



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司


(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

SCIENCE FOR GROWTH SCIENCE FOR LIFE

FIRST QUARTER REPORT 2008





This first quarter report 2008 (in both English and Chinese versions) (“Q1 Report”) has been posted on the Company’s website at <http://www.ck-lifesciences.com>. Shareholders who have chosen to rely on copies of the Company’s corporate communications (including but not limited to annual reports, summary financial reports (where applicable), half-year reports, summary half-year reports (where applicable), quarter reports, notices of meetings, listing documents, circulars and proxy forms) posted on the Company’s website in lieu of the printed copies thereof may request the printed copy of the Q1 Report.

Shareholders who have chosen to receive the corporate communications using electronic means through the Company’s website and who for any reason have difficulty in receiving or gaining access to the Q1 Report posted on the Company’s website will promptly upon request be sent the Q1 Report in printed form free of charge.

Shareholders may at any time choose to change your choice as to the means of receipt (i.e. in printed form or by electronic means through the Company’s website) and/or the language of the Company’s corporate communications by notice in writing to the Company’s Branch Share Registrar, Computershare Hong Kong Investor Services Limited at Rooms 1806-1807, 18th Floor, Hopewell Centre, 183 Queen’s Road East, Hong Kong.

Shareholders who have chosen to receive printed copy of the corporate communications in either English or Chinese version will receive both English and Chinese versions of this Q1 Report since both languages are bound together into one booklet.

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

The principal means of information dissemination on GEM is publication on the internet website operated by the Stock Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed issuers.

This document, for which the directors (the “Directors”) of CK Life Sciences Int’l. (Holdings) Inc. (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this document is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this document misleading; and (iii) all opinions expressed in this document have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

CHAIRMAN'S STATEMENT

The First Quarter Results

HK\$ Million	(Restated)		Variance
	Q1 2008	Q1 2007	
Turnover	785.3	503.4	+ 56%
Profit before fair value changes of financial instruments	32.0	2.1	+ 1423%
Fair value changes on financial instruments	(28.6)	28.0	N/A
Profit attributable to shareholders	3.4	30.1	- 89%

The operations of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Group") delivered a strong performance during the first quarter of 2008, driven by increased sales from health and agriculture-related businesses. Turnover grew by 56% to reach HK\$785 million.

For the first quarter, profit before fair value changes of financial instruments was HK\$32 million, representing a 14-fold growth as compared to the same period last year. This reflects the sound fundamentals and continuing growth momentum from our diverse portfolio of businesses around the world.

After adjusting for the downward valuation of the Group's financial instruments at 31 March 2008 versus 31 December 2007, the Group's profit attributable to shareholders has become HK\$3.4 million, which amounts to an 89% decrease as compared to the same period last year.

It is worth highlighting that the downward valuation of the Group's financial instruments at quarter end, which was caused by the global credit crisis and financial market downturn, is a non-cash accounting entry and is included in the Group's income statement as required by the generally accepted accounting principles in Hong Kong. It has no impact on CK Life Sciences' cashflow and operational profitability for the quarter under review.

The Board of Directors has not declared any dividend for the period under review (2007: Nil).

HEALTH SALES APPROACHED HK\$500 MILLION MARK

During the first quarter, our nutraceutical businesses generated sales totaling HK\$495 million, a 30% increase as compared with the same period last year.

Following acquisitions over the past three years, our nutraceutical portfolio comprises of businesses in Hong Kong, Canada, the United States and Australia. Our quality portfolio has achieved steady results during the period under review. Both our *AG Natural Health (Adrien Gagnon)* nutraceutical business and our custom manufacturing operations through Vitaquest International Holdings LLC performed well during the first quarter and we expect this to continue.

The period under review represented the first quarter of full revenue contribution from Lipa Pharmaceuticals Limited, a leading Australian contract manufacturer of complementary healthcare and over-the-counter medicines that was acquired and privatized by CK Life Sciences in November last year. This acquisition has not only expanded the Group's geographical reach, but also broadened the base of revenue and profit contribution.

AGRICULTURE-RELATED SALES MORE THAN DOUBLED

Revenue of HK\$282 million was recorded by the Group's agriculture-related businesses during the first quarter, representing a significant 147% increase as compared with the same period last year.

Our range of eco-fertilizer products is now being marketed and sold in Asia as well as Australia.

The acquisition of Accensi Pty Ltd, the largest independent contract manufacturer of crop protection products in Australia, was completed during the first quarter and has started to provide profit contribution to the Group.

Following the acquisition, CK Life Sciences now has a portfolio of five agriculture operations in Australia, with manufacturing facilities in four states, namely South Australia, New South Wales, Western Australia and Queensland. Our businesses in Australia have performed well during the period under review. They have benefited from the increased rainfall in the first quarter and improved pricing worldwide.

CONTINUED PROGRESS IN R&D

We have continued to make good progress in our R&D initiatives.

Our pain management product has proceeded to Phase III clinical trials and the patient recruitment process is now underway. Using a technology platform based on tetrodotoxin, the product is designed to ease pain, particularly amongst cancer patients. The trials are being conducted by WEX Pharmaceuticals Inc., a Canadian listed company in which CK Life Sciences has a significant stake.

With regards to our melanoma skin cancer vaccine, discussion continues with the US FDA to determine the course of action necessary for proceeding with Phase III clinical trials.

CK Life Sciences is also carrying out cancer treatment research in a number of other areas. In particular, our research on a liver cancer treatment has been progressing well.

PROSPECTS

Looking ahead, we will continue to nurture the organic growth of our existing businesses and maximize the potential of our recently acquired companies. We will also continue to seek new opportunities for acquisition to further enhance our portfolio and increase revenue channels for the Group.

CK Life Sciences is in relatively advanced stages of development for several of our R&D initiatives. We will continue to dedicate resources to expediting our progress in this key area.

I would like to take this opportunity to thank our shareholders, Board of Directors, staff and business partners for their continued support.

Li Tzar Kuoi, Victor

Chairman

Hong Kong, 15 May 2008

UNAUDITED CONSOLIDATED RESULTS

	Notes	For the three months ended 31 March	
		2008 HK\$'000	2007 HK\$'000 (Restated)
Turnover	2	785,320	503,375
Cost of sales		(527,787)	(331,089)
		257,533	172,286
Other income, gains and losses	3	(32,130)	34,019
Staff costs	4	(88,156)	(68,536)
Depreciation		(7,713)	(7,935)
Amortization of intangible assets		(11,529)	(7,687)
Other operating expenses		(95,367)	(85,564)
Finance costs		(17,346)	(5,981)
Share of results of associates		(1,547)	(1,831)
Profit before taxation		3,745	28,771
Taxation	5	(341)	1,131
Profit for the period		3,404	29,902
Attributable to:			
Equity holders of the Company		3,377	30,103
Minority interests		27	(201)
		3,404	29,902
Earnings per share	6		
– Basic		0.03 cent	0.31 cent
– Diluted		0.03 cent	0.31 cent

NOTES:

1. BASIS OF PREPARATION

The unaudited consolidated results have been prepared in accordance with the Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants and the disclosure requirements of the GEM Listing Rules.

The unaudited consolidated results have been prepared under the historical cost convention, except for certain properties and financial instruments which are measured at revalued amounts or fair values.

The accounting policies used in preparing the unaudited consolidated results are consistent with those used in the Group's annual financial statements for the year ended 31 December 2007.

2. TURNOVER

Turnover represents net invoiced value of goods sold, after allowance for returns and trade discount, as well as income from investments, and is analysed as follows:

	For the three months ended 31 March	
	2008 HK\$'000	2007 HK\$'000 (Restated)
Environment	281,683	114,256
Health	495,322	381,376
Investment *	8,315	7,743
	785,320	503,375

* In previous periods, the sale proceeds and costs in respect of the disposal of trading equity securities were included in the Group's turnover and cost of sales, respectively. In the current period, the Group considered it is more appropriate to include the net balances of sales proceeds amounted to HK\$10,968,000 (2007: HK\$417,000) and the related cost amounted to HK\$10,496,000 (2007: HK\$242,000) in net gain on investment at fair value through profit or loss included in other income, gains and losses. In addition, the decrease in fair value change of investments at fair value through profit or loss / derivative financial instruments amounted to HK\$28,683,000 (2007: increase in fair value of HK\$28,038,000) are reclassified and included in net gain / (loss) on investment at fair value through profit or loss / derivative financial instruments under other income, gains and losses, the comparative amounts have been restated to conform with the current period presentation.

3. OTHER INCOME, GAINS AND LOSSES

	For the three months ended 31 March	
	2008 HK\$'000	2007 HK\$'000 (Restated)
Included in other income, gains and losses are:		
Interest income from bank deposits	5,302	4,519
Net (loss) / gain on investment at fair value through profit or loss, and derivative financial instruments *	(40,922)	28,213

* The amount includes the decrease in fair value change of investments at fair value through profit or loss / derivative financial instruments amounted to HK\$28,683,000 (2007: increase in fair value of HK\$28,038,000).

4. STAFF COSTS

Staff costs which include salaries, bonuses, retirement benefit scheme contributions and recruitment costs for the period under review amounted to HK\$154.5 million (2007: HK\$121.0 million) of which HK\$4.3 million (2007: HK\$4.7 million) relating to development activities was capitalized and HK\$62.0 million (2007: HK\$47.8 million) relating to direct labor costs was included in cost of sales.

5. TAXATION

	For the three months ended 31 March	
	2008 HK\$'000	2007 HK\$'000
Current tax		
Hong Kong	(3)	3,443
Other jurisdictions	7,668	(2,594)
Deferred tax		
Other jurisdictions	(7,324)	(1,980)
	341	(1,131)

Hong Kong profits tax has been provided at the rate of 16.5% (2007: 17.5%). Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

6. EARNINGS PER SHARE

The calculations of the basic and diluted earnings per share attributable to the equity holders of the Company are based on the following data:

	For the three months ended 31 March	
	2008 HK\$'000	2007 HK\$'000
Profit for the period		
Profit for calculating basic and diluted earnings per share	3,377	30,103
Number of shares		
Weighted average number of ordinary shares in issue used in the calculation of basic and diluted earnings per share	9,611,072,400	9,611,072,400

The computation of diluted earnings per share does not assume the exercise of the Company's outstanding share options for the three months respectively ended 31 March 2008 and 2007.

7. DIVIDENDS

No dividend has been declared by the Board of Directors for the three months ended 31 March 2008 (2007: Nil).

UNAUDITED CONSOLIDATED RESULTS (CONT'D)

8. MOVEMENTS OF RESERVES

	Share premium HK\$'000	Investment revaluation reserve HK\$'000	Exchange reserve HK\$'000	Employee share-based compensation reserve HK\$'000	Accumulated losses HK\$'000	Total HK\$'000
2007						
At 1 January 2007	4,147,543	(22,945)	27,226	8,712	(175,190)	3,985,346
Gain on fair value changes of available-for-sale investments	–	2,347	–	–	–	2,347
Employee's share option lapse during the period	–	–	–	(689)	689	–
Exchange difference on translation of financial statements of overseas operations	–	–	(328)	–	–	(328)
Profit for the three months ended 31 March 2007	–	–	–	–	30,103	30,103
At 31 March 2007	4,147,543	(20,598)	26,898	8,023	(144,398)	4,017,468
2008						
At 1 January 2008	4,147,543	(1,795)	93,935	7,291	(56,768)	4,190,206
Release on disposal of investments	–	1,795	–	–	–	1,795
Employee's share option lapse during the period	–	–	–	(429)	429	–
Exchange difference on translation of financial statements of overseas operations	–	–	870	–	–	870
Profit for the three months ended 31 March 2008	–	–	–	–	3,377	3,377
At 31 March 2008	4,147,543	–	94,805	6,862	(52,962)	4,196,248

DIRECTORS' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 31 March 2008, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were required, pursuant to the Model Code on Securities Transactions by Directors adopted by the Company ("Model Code"), to be notified to the Company and the Stock Exchange, were as follows:

(1) LONG POSITIONS IN THE SHARES OF THE COMPANY

Name of Director	Capacity	Number of Ordinary Shares				Total	Approximate % of Shareholding
		Personal Interests	Family Interests	Corporate Interests	Other Interests		
Li Tzar Kuoi, Victor	Beneficial owner & beneficiary of trusts	2,250,000	–	–	4,258,634,570 (Note)	4,260,884,570	44.33%
Kam Hing Lam	Interest of child or spouse	–	6,225,000	–	–	6,225,000	0.06%
Ip Tak Chuen, Edmond	Beneficial owner	2,250,000	–	–	–	2,250,000	0.02%
Yu Ying Choi, Alan Abel	Beneficial owner	2,250,000	–	–	–	2,250,000	0.02%
Chu Kee Hung	Beneficial owner	2,250,000	–	–	–	2,250,000	0.02%
Peter Peace Tulloch	Beneficial owner	1,050,000	–	–	–	1,050,000	0.01%
Wong Yue-chim, Richard	Beneficial owner	375,000	–	–	–	375,000	0.004%
Kwok Eva Lee	Beneficial owner	200,000	–	–	–	200,000	0.002%

DIRECTORS' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES (CONT'D)

Note:

Such 4,258,634,570 shares are held by a subsidiary of Cheung Kong (Holdings) Limited ("Cheung Kong Holdings"). Li Ka-Shing Unity Trustee Company Limited ("TUT") as trustee of The Li Ka-Shing Unity Trust (the "LKS Unity Trust") and companies controlled by TUT as trustee of the LKS Unity Trust hold more than one-third of the issued share capital of Cheung Kong Holdings. Li Ka-Shing Unity Trustee Corporation Limited ("TDT1") as trustee of The Li Ka-Shing Unity Discretionary Trust ("DT1") and Li Ka-Shing Unity Trustcorp Limited ("TDT2") as trustee of another discretionary trust ("DT2") hold all issued and outstanding units in the LKS Unity Trust but are not entitled to any interest or share in any particular property comprising the trust assets of the LKS Unity Trust. The discretionary beneficiaries of such discretionary trusts are, inter alia, Mr. Li Tzar Kuoi, Victor, his wife and children, and Mr. Li Tzar Kai, Richard. Mr. Li Tzar Kuoi, Victor, as a discretionary beneficiary of such discretionary trusts and a Director of the Company, is taken to be interested in those shares of Cheung Kong Holdings and thus is taken to be interested in those 4,258,634,570 shares held by the subsidiary of Cheung Kong Holdings under the SFO.

DIRECTORS' INTERESTS AND SHORT POSITIONS IN SHARES,
UNDERLYING SHARES AND DEBENTURES (CONT'D)

(2) LONG POSITIONS IN THE UNDERLYING SHARES OF THE COMPANY

Pursuant to the share option scheme adopted by the Company on 26 June 2002 (the "Share Option Scheme"), certain Directors in the capacity as beneficial owners were granted unlisted and physically settled share options to subscribe for shares of the Company, details of which as at 31 March 2008 were as follows:

Name of Director	Date of grant	Number of share options				Outstanding as at 31 March 2008	Option period	Subscription price per share HK\$
		Outstanding as at 1 January 2008	Granted during the period	Exercised during the period	Cancelled/lapsed during the period			
Yu Ying Choi,	30/9/2002	348,440	–	–	–	348,440	30/9/2003 – 29/9/2012	1.422
Alan Abel	27/1/2003	775,560	–	–	–	775,560	27/1/2004 – 26/1/2013	1.286
	19/1/2004	775,560	–	–	–	775,560	19/1/2005 – 18/1/2014	1.568
Chu Kee Hung	30/9/2002	348,440	–	–	–	348,440	30/9/2003 – 29/9/2012	1.422
	27/1/2003	775,560	–	–	–	775,560	27/1/2004 – 26/1/2013	1.286
	19/1/2004	775,560	–	–	–	775,560	19/1/2005 – 18/1/2014	1.568

Save as disclosed above, during the three months ended 31 March 2008, none of the Directors or their respective associates was granted share options to subscribe for shares of the Company, nor had exercised such rights.

Save as disclosed above, none of the Directors or chief executive of the Company had, as at 31 March 2008, any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

DETAILS OF OPTIONS GRANTED BY THE COMPANY

The Company has adopted the Share Option Scheme under which the Directors or employees of the Company or its subsidiaries or certain other persons may be granted share options to subscribe for shares of the Company subject to the terms and conditions stipulated in the Share Option Scheme.

As at 31 March 2008, options to subscribe for an aggregate of 13,730,221 shares of the Company granted to certain continuous contract employees (including the Executive Directors of the Company as disclosed above) pursuant to the Share Option Scheme were outstanding, details of which were as follows:

Date of grant	Number of share options						Outstanding as at 31 March 2008	Option period	Subscription price per share HK\$
	Outstanding as at 1 January 2008	Granted during the period	Exercised during the period	Lapsed during the period	Cancelled during the period	Outstanding as at 31 March 2008			
30/9/2002	2,556,538	–	–	(134,880)	–	2,421,658	30/9/2003 – 29/9/2012 (Note 1)	1.422	
27/1/2003	5,603,251	–	–	(247,392)	–	5,355,859	27/1/2004 – 26/1/2013 (Note 2)	1.286	
19/1/2004	6,384,320	–	–	(431,616)	–	5,952,704	19/1/2005 – 18/1/2014 (Note 3)	1.568	

Notes:

1. The options are exercisable from 30 September 2003 to 29 September 2012 (both days inclusive) subject to the following vesting periods:
 - (i) up to 35% of the options commencing on 30 September 2003;
 - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 30 September 2004; and
 - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 30 September 2005.

DETAILS OF OPTIONS GRANTED BY THE COMPANY (CONT'D)

2. The options are exercisable from 27 January 2004 to 26 January 2013 (both days inclusive) subject to the following vesting periods:
 - (i) up to 35% of the options commencing on 27 January 2004;
 - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 27 January 2005; and
 - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 27 January 2006.

3. The options are exercisable from 19 January 2005 to 18 January 2014 (both days inclusive) subject to the following vesting periods:
 - (i) up to 35% of the options commencing on 19 January 2005;
 - (ii) up to 70% of the options (including the options not exercised under the limit prescribed for in the previous period) commencing on 19 January 2006; and
 - (iii) up to 100% of the options (including the options not exercised under the limit prescribed for in the previous periods) commencing on 19 January 2007.

INTERESTS AND SHORT POSITIONS OF SHAREHOLDERS

So far as is known to any Director or chief executive of the Company, as at 31 March 2008, shareholders (other than Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO or were otherwise notified to the Company were as follows:

(1) LONG POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN THE SHARES OF THE COMPANY

Name	Capacity	Number of Ordinary Shares	Approximate % of Shareholding
Gold Rainbow Int'l Limited	Beneficial owner	4,258,634,570	44.30%
Gotak Limited	Interest of a controlled corporation	4,258,634,570 (Note i)	44.30%
Cheung Kong (Holdings) Limited	Interest of controlled corporations	4,258,634,570 (Note ii)	44.30%
Li Ka-Shing Unity Trustee Company Limited as trustee of The Li Ka-Shing Unity Trust	Trustee	4,258,634,570 (Note iii)	44.30%
Li Ka-Shing Unity Trustee Corporation Limited as trustee of The Li Ka-Shing Unity Discretionary Trust	Trustee & beneficiary of a trust	4,258,634,570 (Note iii)	44.30%
Li Ka-Shing Unity Trustcorp Limited as trustee of another discretionary trust	Trustee & beneficiary of a trust	4,258,634,570 (Note iii)	44.30%
Li Ka-shing	Founder of discretionary trusts & interest of controlled corporations	4,258,634,570 (Note iv)	44.30%
Trueway International Limited	Beneficial owner	2,119,318,286	22.05%
Li Ka Shing Foundation Limited	Interest of controlled corporations	2,835,759,715 (Note v)	29.50%

INTERESTS AND SHORT POSITIONS OF SHAREHOLDERS (CONT'D)

(2) LONG POSITION OF OTHER PERSON IN THE SHARES OF THE COMPANY

Name	Capacity	Number of Ordinary Shares	Approximate % of Shareholding
Triluck Assets Limited	Beneficial owner	716,441,429	7.45%

Notes:

- i. This represents the same block of shares in the Company as shown against the name of Gold Rainbow Int'l Limited ("Gold Rainbow") above. Since Gold Rainbow is wholly-owned by Gotak Limited, Gotak Limited is deemed to be interested in the same number of shares in which Gold Rainbow was interested under the SFO.
- ii. As Gotak Limited is wholly-owned by Cheung Kong Holdings, Cheung Kong Holdings is deemed to be interested in the same number of shares which Gotak Limited is deemed to be interested under the SFO.
- iii. TUT as trustee of the LKS Unity Trust and companies controlled by TUT as trustee of the LKS Unity Trust hold more than one-third of the issued share capital of Cheung Kong Holdings. TDT1 as trustee of DT1 and TDT2 as trustee of DT2 hold all issued and outstanding units in the LKS Unity Trust but are not entitled to any interest or share in any particular property comprising the trust assets of the LKS Unity Trust. Under the SFO, each of TUT as trustee of the LKS Unity Trust, TDT1 as trustee of DT1 and TDT2 as trustee of DT2 is deemed to be interested in the same block of shares as Cheung Kong Holdings is deemed to be interested as disclosed in Note ii above.
- iv. As Mr. Li Ka-shing owns one-third of the issued share capital of Li Ka-Shing Unity Holdings Limited which in turn holds the entire issued share capital of TUT, TDT1 and TDT2 and is the settlor and may be regarded as a founder of each of DT1 and DT2 for the purpose of the SFO, Mr. Li Ka-shing is deemed to be interested in the same number of shares in which Cheung Kong Holdings is deemed to be interested as mentioned above under the SFO.
- v. Trueway International Limited ("Trueway") and Triluck Assets Limited ("Triluck") are wholly-owned by Li Ka Shing Foundation Limited ("LKSF") and LKSF is deemed to be interested in a total of 2,835,759,715 shares under the SFO, being the aggregate of the shares in which Trueway and Triluck were interested as shown against the names Trueway and Triluck above.

Save as disclosed above, as at 31 March 2008, the Company has not been notified by any persons (other than Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

COMPETING INTERESTS

During the three months ended 31 March 2008, the interests of Directors, management shareholders of the Company or their respective associates as defined in the GEM Listing Rules (the “Associates”) in the businesses which compete or may compete, either directly or indirectly, with the businesses of the Group (the “Competing Business”) as required to be disclosed pursuant to the GEM Listing Rules were as follows:

(1) CORE BUSINESS ACTIVITIES OF THE GROUP

- (i) Research and development, manufacturing, commercialization, marketing and selling of environmental and human health products.
- (ii) Investment in various financial and investment products.

(2) INTERESTS IN COMPETING BUSINESS

Name of Director	Name of Company	Nature of Interest	Competing Business (Note 2)
Li Tzar Kuoi, Victor	Cheung Kong (Holdings) Limited	Managing Director and Deputy Chairman (Note 1)	(ii)
	Hutchison Whampoa Limited	Executive Director and Deputy Chairman (Note 1)	(i) & (ii)
	Cheung Kong Infrastructure Holdings Limited	Chairman (Note 1)	(i) & (ii)
	Hongkong Electric Holdings Limited	Executive Director (Note 1)	(ii)
Kam Hing Lam	Cheung Kong (Holdings) Limited	Deputy Managing Director (Note 1)	(ii)
	Hutchison Whampoa Limited	Executive Director (Note 1)	(i) & (ii)
	Cheung Kong Infrastructure Holdings Limited	Group Managing Director (Note 1)	(i) & (ii)
	Hongkong Electric Holdings Limited	Executive Director	(ii)

COMPETING INTERESTS (CONT'D)

Name of Director	Name of Company	Nature of Interest	Competing Business (Note 2)
Ip Tak Chuen, Edmond	Cheung Kong (Holdings) Limited	Deputy Managing Director	(ii)
	Cheung Kong Infrastructure Holdings Limited	Executive Director and Deputy Chairman	(i) & (ii)
	TOM Group Limited	Non-executive Director	(ii)
	CATIC International Holdings Limited	Non-executive Director	(ii)
	Excel Technology International Holdings Limited	Non-executive Director	(ii)
	Shougang Concord International Enterprises Company Limited	Non-executive Director	(ii)
	The Ming An (Holdings) Company Limited	Non-executive Director	(ii)
	ARA Asset Management Limited	Non-executive Director	(ii)
	Ruinian International Limited	Director	(i)
Yu Ying Choi, Alan Abel	Wex Pharmaceuticals Inc.	Director	(i)
Wong Yue-chim, Richard	Great Eagle Holdings Limited	Independent Non-executive Director	(ii)
	Orient Overseas (International) Limited	Independent Non-executive Director	(ii)
Kwok Eva Lee	Cheung Kong Infrastructure Holdings Limited	Independent Non-executive Director	(i) & (ii)
Colin Stevens Russel	Cheung Kong Infrastructure Holdings Limited	Independent Non-executive Director	(i) & (ii)
	ARA Asset Management Limited	Independent Non-executive Director	(ii)

Notes:

1. Apart from holding the directorships, Mr. Li Tzar Kuoi, Victor and Mr. Kam Hing Lam and/or their respective family members have direct and/or indirect interests in the shares of such companies where appropriate.
2. Such businesses may be made through subsidiaries, associated companies or by way of other forms of investments.

Save as disclosed above, none of the Directors, the management shareholders of the Company or their respective Associates have any interests in a business which competes or may compete, either directly or indirectly, with the businesses of the Group.

OTHER INFORMATION

CORPORATE GOVERNANCE

The Board of Directors (“Board”) and the management of the Company are committed to the maintenance of good corporate governance practices and procedures. The corporate governance principles of the Company emphasize a quality Board, sound internal controls, and transparency and accountability to all shareholders. The Company has applied the principles and complied with all code provisions and, where applicable, the recommended best practices of the Code on Corporate Governance Practices (“Code on CG Practices”) as set out in Appendix 15 of the GEM Listing Rules throughout the three months ended 31 March 2008.

(1) Board Composition and Board Practices

The Board is collectively responsible for the oversight of the management of the business and affairs of the Group with the objective of enhancing shareholders value. The Board consists of a total of nine Directors, comprising five Executive Directors, one Non-executive Director and three Independent Non-executive Directors. One-third of the Board are Independent Non-executive Directors and at least one of them has appropriate professional qualifications, or accounting or related financial management expertise as required by the GEM Listing Rules. All Directors (including Non-executive Directors) are subject to retirement by rotation once every three years in accordance with the Company’s Articles of Association and the Code on CG Practices.

The positions of the Chairman of the Board (“Chairman”) and the Chief Executive Officer are held by separate individuals with a view to maintaining an effective segregation of duties respecting management of the Board and the day-to-day management of the Group’s business.

All Directors have made active contribution to the affairs of the Board and the Board has always acted in the best interests of the Group. In addition to regular Board meetings, the Chairman has meetings with the Non-executive Directors (including the Independent Non-executive Directors) without the presence of Executive Directors at least once every year.

The Company Secretary is responsible to the Board for ensuring that Board procedures are followed and for ensuring that the Board is briefed on all legislative, regulatory and corporate governance developments and that the Board has regard to them when making decisions. The Company Secretary and the Compliance Officer are also directly responsible for the Group’s compliance with the continuing obligations of the GEM Listing Rules, Codes on Takeovers and Mergers and Share Repurchases, Companies Ordinance, SFO and other applicable laws, rules and regulations.

The Company has adopted the model code on securities transactions by directors of listed issuers set out in Chapter 5 of the GEM Listing Rules as its own code of conduct regarding Directors' securities transactions, effective 31 March 2004.

(2) Internal Controls

The Company has an internal audit function in place to provide an independent assessment of the Group's internal control system and review of its effectiveness in accordance with the Code on CG Practices. The Internal Audit Department prepares its audit plan using a risk based methodology in consultation with, but independent of, the management for review by the audit committee of the Company ("Audit Committee"). The audit work focuses on financial, functional and information technology areas within the audited business units and those areas of the Group's activities with significant perceived risks. An integral part of the internal audit function is to monitor and ensure effective implementation of these internal control systems.

(3) Audit Committee

The Company established the Audit Committee on 26 June 2002 and has formulated its written terms of reference in accordance with the provisions set out in the Code on CG Practices. The Audit Committee comprises three Independent Non-executive Directors, namely, Professor Wong Yue-chim, Richard (Chairman of the Audit Committee), Mrs. Kwok Eva Lee and Mr. Colin Stevens Russel. The principal duties of the Audit Committee include the review and supervision of the Group's financial reporting system and internal control procedures, review of the Group's financial information and review of the relationship with the external auditors of the Company.

The Group's first quarter report for the three months ended 31 March 2008 has been reviewed by the Audit Committee.

(4) Remuneration Committee

According to the Code on CG Practices, the Company established its remuneration committee ("Remuneration Committee") on 1 January 2005 with a majority of the members being Independent Non-executive Directors. The Remuneration Committee comprises the Chairman of the Board, Mr. Li Tzar Kuoi, Victor (Chairman of the Remuneration Committee), and two Independent Non-executive Directors, namely, Mrs. Kwok Eva Lee and Mr. Colin Stevens Russel.

The principal responsibilities of the Remuneration Committee include making recommendations to the Board on the Company's policy and structure for the remuneration of Directors and senior management, and reviewing the specific remuneration packages of all Executive Directors and senior management by reference to corporate goals and objectives resolved by the Board from time to time.

(5) Investor Relations and Communication with Shareholders

The Company establishes different communication channels with shareholders and investors, including (i) printed copies of financial reports, circulars, notices of general meetings and proxy forms required under the GEM Listing Rules, and shareholders can select to receive such documents by electronic means; (ii) the annual general meeting provides a forum for shareholders to raise comments and exchange views with the Board; (iii) updated and key information of the Group is available on the website of the Company; (iv) the Company's website offers a main communication channel between the Company and its shareholders and stakeholders; (v) regular press conferences and briefing meetings with analysts are arranged from time to time to update interested parties on the performance of the Group; (vi) the Company's Branch Share Registrar deals with shareholders for share registration and related matters; and (vii) Corporate Affairs Department of the Company handles enquiries from shareholders and investors generally.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the three months ended 31 March 2008, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

DISCLOSURE UNDER RULE 17.23 OF THE GEM LISTING RULES

On 13 May 2005, two indirect wholly-owned subsidiaries of the Company had each entered into a loan facility letter with HSBC Bank Canada ("Loan Facility Agreements") in connection with or arising out of the acquisition of the entire issued and outstanding shares in the capital of Développement Santé Naturelle A.G. Ltée. One of the Loan Facility Agreements is for a 3-year term loan (the "Term Loan") and the other is for an operating facility (together the "Facilities") under which the Company guarantees the obligations of its wholly-owned subsidiaries under the Facilities. In March 2008, the Facilities were renewed and the maturity date of the Term Loan was extended to 15 May 2011. As at 31 March 2008, the outstanding balance of the Facilities amounted to HK\$133,954,388. The provisions of the Loan Facility Agreements require that unless the Facilities have been repaid in full, at least 44.01% direct or indirect interest in the Company will have to be maintained by Cheung Kong Holdings (the Company's controlling shareholder). This obligation has been complied with.

CORPORATE INFORMATION AND KEY DATE

BOARD OF DIRECTORS

Executive Directors

LI Tzar Kuoi, Victor

Chairman

KAM Hing Lam

President and Chief Executive Officer

IP Tak Chuen, Edmond

Senior Vice President and

Chief Investment Officer

YU Ying Choi, Alan Abel

Vice President and Chief Operating Officer

CHU Kee Hung

Vice President and Chief Scientific Officer

Non-executive Directors

Peter Peace TULLOCH

Non-executive Director

WONG Yue-chim, Richard

Independent Non-executive Director

KWOK Eva Lee

Independent Non-executive Director

Colin Stevens RUSSEL

Independent Non-executive Director

AUDIT COMMITTEE

WONG Yue-chim, Richard

Chairman

KWOK Eva Lee

Colin Stevens RUSSEL

REMUNERATION COMMITTEE

LI Tzar Kuoi, Victor

Chairman

KWOK Eva Lee

Colin Stevens RUSSEL

COMPANY SECRETARY

Eirene YEUNG

QUALIFIED ACCOUNTANT

MO Yiu Leung, Jerry

COMPLIANCE OFFICER

YU Ying Choi, Alan Abel

AUTHORIZED REPRESENTATIVES

IP Tak Chuen, Edmond

Eirene YEUNG

AUDITORS

Deloitte Touche Tohmatsu

PRINCIPAL BANKERS

The Hongkong and Shanghai Banking Corporation Limited
JP Morgan Chase Bank, N.A.
Canadian Imperial Bank of Commerce
Commonwealth Bank of Australia
Citibank, N.A.

LEGAL ADVISERS

Woo, Kwan, Lee & Lo
DLA Piper Hong Kong

REGISTERED OFFICE

P.O. Box 309GT
Ugland House
South Church Street
Grand Cayman
Cayman Islands

HEAD OFFICE

2 Dai Fu Street
Tai Po Industrial Estate
Tai Po
Hong Kong

PRINCIPAL PLACE OF BUSINESS

7th Floor, Cheung Kong Center
2 Queen's Road Central
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Butterfield Fund Services (Cayman) Limited
Butterfield House
68 Fort Street, P.O. Box 705
George Town
Grand Cayman
Cayman Islands

BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited
Rooms 1712-1716, 17th Floor, Hopewell Centre
183 Queen's Road East, Hong Kong

STOCK CODES

The Stock Exchange of Hong Kong Limited: 8222
Bloomberg: 8222 HK
Reuters: 8222.HK

WEBSITE

<http://www.ck-lifesciences.com>

KEY DATE

First Quarter Results Announcement 15 May 2008